SCHEMBL18220148

SCHEMBL18220148

COCCNS(=O)(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCN(C)CC4)ccc3c2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.43
OPRM1 P35372 3/20 0.40
OPRD1 P41143 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPKAPK2 P49137 1/20 0.39
APAF1 O14727 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
RAD52 P43351 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
ERN1 O75460 1/20 0.35
CSF1R P07333 4/20 0.35
POLB P06746 1/20 0.35
PRKD1 Q15139 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24075180 0.94 APP (0.41) APPOPRM1OPRD1MEN1KMT2A
SCHEMBL18220136 0.93 APP (0.42) APPMEN1KMT2AMAPKAPK2MAPK1
SCHEMBL18220151 0.92 APP (0.44) APPMEN1KMT2AMAPKAPK2SMN1; SMN2
SCHEMBL18220263 0.86 OPRM1 (0.37) APPOPRM1OPRD1MEN1KMT2A
SCHEMBL24075179 0.86 APP (0.42) APPMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL17120662 0.86 OPRM1 (0.37) APPOPRM1OPRD1MEN1KMT2A
SCHEMBL18220008 0.85 APP (0.48) APPMEN1KMT2AALDH1A1MAPT
SCHEMBL18220195 0.84 APP (0.43) APPMEN1KMT2AALDH1A1MAPT
SCHEMBL18220129 0.84 APP (0.47) APPOPRM1OPRD1MEN1KMT2A
SCHEMBL18221618 0.84 OPRM1 (0.36) APPOPRM1OPRD1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10934264-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-02 US disclosed
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-04-23 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885OPRM1 4377/4885OPRD1 4481/4885
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885OPRM1 4377/4885OPRD1 4481/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885OPRM1 4377/4885OPRD1 4481/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885OPRM1 4421/4885OPRD1 4497/4885
US-10934264-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885OPRM1 4377/4885OPRD1 4481/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885OPRM1 4421/4885OPRD1 4497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.